YNDX - RSX: Sputnik V Vaccine Will Forever Change The Value Of 'Made In Russia' Brand

• After decades of exporting poor quality Soviet manufactured products, and decades more of post-communist struggles, the "Made in Russia" brand suffered a great deal of damage.
• Russia has been trying to break the poor brand reputation, but a failure to break through on the international market with value-added products relegates RSX to being a commodities-dominated fund.
• The COVID crisis provided Russia with a huge opportunity, which it seems they managed to capitalize on, by producing a seemingly safe and highly effective vaccine.
• RSX stands to benefit greatly, given that there are other potentially successful industrial projects, waiting to capitalize on the Sputnik V success, which could transform Russia's economy this decade.
• There are other factors that suggest the RSX fund is set to do well.  For instance, the view on Russian energy is far too pessimistic, due to unrealistic expectations for green energy.

For further details see: